Anticancer activity, intrinsic

Some synthetic macromolecules have shown intrinsic anticancer activity. Their mechanism of action is probably either the direct action upon the tumor cell, or the stimulation of the host s immune system [59] (Table 2). We do not exclude the use of such macromolecules as drug carriers in the future. However, the combination of a biologically active carrier with a biologically active drug makes the evaluation of the structure-property relationships more difficult. 

Table 2. Polymers with intrinsic anticancer activity...

Breslow DS (1976) Biologically active synthetic polymers. Pure Appl Chem 46 103-13 Seymour LW (1991) Synthetic polymers with intrinsic anticancer activity. J Bioact Comp Polymers 6 178-216... 

Dufes C, Keith WN, Biisland A, Proutski I, Uchegbu IF, Schatzlein AG (2005) Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res 65 8079-8084... 

Because of the severe side effects, the restricted tumour spectrum and the acquired or intrinsic resistance, alternative metal-based anticancer drugs are being actively pursued. Ruthenium compounds containing Ru or Ru are considered to be suitable candidates two mthenium(III) complexes have entered clinical trials, trans-[RuCl4(DMSO)(Im)]ImH (NAMI-A, where Im = imidazole) and trans-[RuCl4(Ind)2]IndH (KP1019, where Ind = indazole). This is the mthenium complex, their stmctures are presented in Figure 22.9. There are two... 

In general, particulate drug carriers can be used to reverse MDR by three ways (1) intrinsic MDR reversal activities of drug carriers (2) encapsulation and delivery of MDR reversal agents (3) delivery of combinational therapy or unconventional anticancer agents and (4) bypassing the membrane transporter resistance mechanisms. Some researchers also combined more than one of these approaches to obtain additional MDR reversal activity. 

Dvorakova K, Payne CM, Landowski TH, Tome ME, Halperin DS, Dorr RT. Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. Anticancer Drugs 2002 13(10) 1031-42. 

---